Share

Why The Next Big Thing Might Not Be, After All

Arlin Wasserman questions the viewpoint that GLP-1 drugs will have a major impact on the food industry.
Idea loading concept with light bulb and loading bar.
Arlin Wasserman, MS Arlin Wasserman

Food Technology Magazine

You’ve flipped through the March issue of Food Technology and learned of the many areas of innovation in our industry made possible by the arrival of GLP-1 drugs like Ozempic, which many now consider to be The Next Big Thing.

The food industry is always seeking The Next Big Thing because significant changes in the business of food are rare events. New flavors, brands, or packaging can certainly win business from established competitors, and new superfoods, super ingredients, and functionality can win converts.

But stubbornly, the overall consumption of food—and demand for our industry’s products—doesn’t grow much faster than …

Login or Sign Up To Continue

You’ve hit your limit of free articles. Either sign in to your existing account, or sign up to be an IFT member and get access to hundreds of digital resources and articlers.

Login Become a Member

Hero Image: © treety/iStock/Getty Images Plus

Authors

  • Arlin Wasserman, MS

    Arlin Wasserman Food Industry Advisor


    Arlin Wasserman is the founder and managing director of Changing Tastes, where he helps companies identify and catalyze shifts in the way business and consumers think about food.

Categories

  • Food Health Nutrition

  • Obesity and Weight Management

  • Diet and Health

  • Dialogue

  • Food Technology Magazine